Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Assessment of the Changes in Cortical and Medullary Renal Blood Flow During Exercise in Healthy Subjects Using Contrast Enhanced Ultrasound

10 mei 2017 bijgewerkt door: Kambiz Kalantarinia, University of Virginia
Renal parenchymal blood flow can be divided in cortical and medullary blood flow. Changes and factors affecting renal medullary blood flow have not been studied in detail previously as investigators/doctors did not have tools to monitor renal medullary blood flow in vivo. Since Trueta first described renal medullary blood flow, multiple attempts have been made to study renal medullary blood flow using invasive methods. Recently renal medullary blood flow measurement using contrast US has emerged as a promising technique that investigators can use to study renal medullary blood flow in vivo. In this study investigators are aiming to study changes in renal parenchymal (cortical and medullary) blood flow with exercise in healthy subject.

Studie Overzicht

Gedetailleerde beschrijving

This study requires a screening day and two visits on separate days to the Clinical Research Unit (CRU). Three visits total.

Screening Visit:

  1. The subjects will undergo detailed history and physical examination.
  2. The inclusion and exclusion criteria will be reviewed.
  3. The details of the study procedures, potential risks and benefits will be reviewed with each subject and all potential questions will be answered.
  4. Subjects' understating of all details of the study components will be ascertained and they will be asked to sign the informed consent form.
  5. A copy of the signed informed consent will be placed in study file and another copy will be provided to each subject.
  6. The study visit day will be scheduled within 2 weeks of the screening day.
  7. All subjects will be asked to arrive on their first study day after an overnight fast. They will be instructed to avoid caffeine and exercise for 24 hours.

Study Day #1 The subjects will arrive in the CRU in the morning. Subjects' understanding of all study related procedures will be assessed and all remaining questions will be answered. The following sequence of procedures will be followed for all enrolled subjects.

  1. Physical exam including vital signs (Blood Pressure, Heart Rate, Weight, Height, Respiration Rate, Temperature)
  2. Urine pregnancy test for women of child bearing age. If positive, subjects will be excluded.

    Determination of peak oxygen consumption

  3. Subjects will complete a continuous VO2 peak bicycle ergometer protocol.

    1. Each subject will start peddling on a stationary bike
    2. The initial power output (PO) will be set at 20 watts
    3. The power output will be increased by 15 watts every 2-minutes until volitional exhaustion.
    4. Metabolic data will be collected during the protocol using standard open-circuit spirometric techniques (Viasys Vmax Encore, Yorba Linda, CA)
    5. Heart rate was assessed electrocardiographically.
    6. VO2 peak will be chosen as the highest VO2 attained during the exercise protocol

On Day 2 of testing

  1. Check Vitals (BP, HR, Wt., RR, Temp.)
  2. Insert peripheral IV line Baseline renal blood flow measurement using contrast enhanced ultrasonography
  3. The Definity vial will be placed at room temperature before being used. It will be activated after shaking the vial using Vialmax® for 45 seconds. It will be used immediately after activation.
  4. 0.4 ml of Definity will be mixed in 10 ml of preservative free saline.
  5. Infusion of Definity into a peripheral vein will be started at 2 ml/min and titrated for optimal image quality using a minipump (not to exceed 10 ml/min at any time).
  6. Baseline contrast ultrasound imaging of right kidney will be performed with low mechanical index (MI) of 0.2.
  7. 4 - 5 ultrasound impulses with high MI of 1.0 and duration of 1 second will be used to destruct the microbubbles in the kidney tissue
  8. Ultrasound imaging of the kidney with low MI (0.2) will continue immediately after each impulse for several seconds.
  9. Infusion of Definity will stop at this point.
  10. Vital signs will be monitored every 15 minutes and continuous pulse oximetry will be performed during Definity administration.
  11. Vital signs and pulse oximetry will be monitored every 15 minutes until 30 minutes after discontinuation of Definity.
  12. A urine dipstick will be performed by the study team 30 minutes after completion of Definity infusion if a sample is available.

    Constant load Exercise protocol

  13. Subjects will complete 30 minutes of continuous cycling at the power output associated with 85% of VO2peak from the continuous bicycle ergometer protocol. Metabolic data will be collected as described above.
  14. Once metabolic parameter are reached, exercise will be stopped and subject will be asked to lie down on the bed Renal Blood flow measurement following exercise using contrast enhanced ultrasonography
  15. Immediately after completion of exercise protocol, steps 5 - 12 under day 2 procedures will be repeated.
  16. The study procedures will end at this point.

Studietype

Ingrijpend

Inschrijving (Verwacht)

19

Fase

  • Fase 2
  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Virginia
      • Charlottesville, Virginia, Verenigde Staten, 22908
        • Werving
        • University of Virginia
        • Contact:
        • Contact:
        • Hoofdonderzoeker:
          • Kambiz Kalantarinia, MD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 50 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Healthy Adult - 18 to 50 years old
  • All ethnicity and genders

Exclusion Criteria:

  • Pregnancy or lactation
  • Active infection
  • Hypertension
  • Chronic Medication Use except Multi Vitamin Use and Birth Control Medications
  • Known history of a right to left intra-cardiac shunt
  • Known history of pulmonary hypertension, including porto-pulmonary hypertension
  • History of allergies to Definity®
  • History of Liver or Kidney Transplant
  • Patient on hemodialysis
  • Has received iodinated contrast within 72 hours of admission to study

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Diagnostisch
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Healthy Test Subjects
We will be using the drug Definity that is an approved medication for cardiac contrast enhanced ultrasound to measure the changes in kidney blood flow with exercise in healthy subjects.
Andere namen:
  • stilstaande fiets
During kidney ultrasound, Definity microbubbles will be injected into the vein to see how blood flows through the kidneys
Andere namen:
  • ultrasound contrast agent or microbubbles
This done before and after exercise with the help of Definity to see changes in kidney blood flow
Andere namen:
  • Renal Ultrasound examination

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in renal blood flow in exercise as assessed by CEUS
Tijdsspanne: Before and immediately after exercise
Total, cortical and medullary kidney blood flow will be measured using contrast-enhanced ultrasonography
Before and immediately after exercise

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Kambiz Kalantarinia, MD, University of Virginia, Department of Nephrology

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 januari 2016

Primaire voltooiing (Verwacht)

1 augustus 2017

Studie voltooiing (Verwacht)

1 oktober 2017

Studieregistratiedata

Eerst ingediend

25 januari 2016

Eerst ingediend dat voldeed aan de QC-criteria

29 januari 2016

Eerst geplaatst (Schatting)

3 februari 2016

Updates van studierecords

Laatste update geplaatst (Werkelijk)

12 mei 2017

Laatste update ingediend die voldeed aan QC-criteria

10 mei 2017

Laatst geverifieerd

1 mei 2017

Meer informatie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren